in the Q&A that without the growth expenditure they would essentially stay sub scale and run into problems down the track.
- Forums
- ASX - By Stock
- BEO
- Ann: Skyfii Quarterly Business Review and Appendix 4C
Ann: Skyfii Quarterly Business Review and Appendix 4C, page-13
Featured News
Add BEO (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.25M |
Open | High | Low | Value | Volume |
3.5¢ | 3.5¢ | 3.4¢ | $47.87K | 1.374M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300000 | 3.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 720489 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300000 | 0.032 |
1 | 209264 | 0.030 |
1 | 134176 | 0.029 |
1 | 350000 | 0.026 |
1 | 54545 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 720489 | 2 |
0.039 | 77428 | 1 |
0.040 | 300000 | 1 |
0.043 | 50000 | 1 |
0.050 | 69420 | 2 |
Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
Featured News
BEO (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online